Trial Profile
A Phase II Study of Sorafenib in Combination With Docetaxel in Patients With Androgen-Independent Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Sorafenib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Biomarker; Therapeutic Use
- 21 Mar 2019 Status changed from recruiting to completed.
- 06 Feb 2008 New trial record.